Norgestimate-Ethinyl Estradiol Formulations and Risks

Norgestimate-ethinyl estradiol is a combined oral contraceptive that pairs a low-androgenic progestin (norgestimate) with a synthetic estrogen (ethinyl estradiol) to prevent pregnancy and, in certain formulations, treat moderate acne. It is one of the most widely prescribed birth control pills in the United States, sold under brand names like Ortho Tri-Cyclen, Ortho-Cyclen, Sprintec, and Tri-Sprintec, among many generics. What makes it distinctive among hormonal contraceptives is norgestimate’s unusually favorable balance between strong progestational activity and weak androgenic side effects, a profile that shapes everything from its skin-clearing reputation to its cardiovascular risk profile.

How Norgestimate Works in the Body

Norgestimate is what pharmacologists call a prodrug. On its own, it binds only weakly to progesterone receptors. Once you swallow it, your body rapidly converts it into active metabolites, primarily levonorgestrel-17-acetate and levonorgestrel, which do the actual work of suppressing ovulation and thickening cervical mucus. Receptor-binding studies showed that norgestimate itself had a binding affinity to the progesterone receptor of less than 1% compared to a reference compound, while levonorgestrel-17-acetate bound at roughly the same strength as levonorgestrel itself.¹ This two-step activation matters because it explains a seeming paradox: norgestimate is metabolized into levonorgestrel, which is one of the more androgenic progestins on the market, yet norgestimate-containing pills behave as though the progestin is only weakly androgenic. The explanation lies in the fact that its metabolic pathway produces intermediate compounds that bind progesterone receptors well but androgen receptors poorly.

When researchers compared norgestimate’s androgenic receptor binding to that of other progestins, norgestimate showed the best selectivity ratio of the group. Its binding to androgen receptors was a tiny fraction of what you see with levonorgestrel, gestodene, or the active metabolite of desogestrel.² This selectivity was the entire design goal. Older progestins caused side effects like acne, excess hair growth, and unfavorable cholesterol shifts because they activated androgen receptors. Norgestimate was engineered specifically to minimize those effects while still being a potent contraceptive.³

Contraceptive Effectiveness

In clinical trials, norgestimate-ethinyl estradiol performs well as a contraceptive. A monophasic formulation containing 250 micrograms of norgestimate with 35 micrograms of ethinyl estradiol demonstrated a Pearl index of 0.25, meaning fewer than one pregnancy per 400 women using it for a year under ideal conditions.⁴ That number reflects perfect use. In more typical real-world conditions, a head-to-head trial comparing Ortho Tri-Cyclen Lo (the lower-dose triphasic version) with another oral contraceptive found overall pregnancy probabilities of about 2% through 13 cycles.⁵ That gap between ideal and typical use exists for all oral contraceptives and mostly reflects missed pills rather than drug failure.

One ovulation-suppression study tested several norgestimate-ethinyl estradiol regimens and found that none of the women on Ortho Tri-Cyclen Lo showed signs of ovulation during the monitored cycle, based on progesterone levels.⁶ Cycle control, meaning predictable periods with minimal spotting between them, was consistently described as reliable across trials.⁷

Triphasic Versus Monophasic Formulations

Norgestimate-ethinyl estradiol comes in both monophasic versions (same dose every day) and triphasic versions (the norgestimate dose steps up across three phases of the cycle while ethinyl estradiol stays the same or shifts slightly). The triphasic design was meant to mimic the body’s natural hormonal fluctuations, and some manufacturers marketed it as more “physiological.” In practice, a direct comparison trial found that cycle control was similar between monophasic and triphasic norgestimate pills.⁸

A Cochrane systematic review looking at triphasic versus monophasic pills more broadly found that about half the included trials reported slightly better bleeding patterns with triphasic regimens, but the differences were inconsistent across studies and no clear winner emerged for discontinuation rates or side effects.⁹ For most people, the choice between triphasic and monophasic norgestimate-ethinyl estradiol is a matter of preference and insurance coverage rather than a meaningful clinical difference.

Acne Treatment

The triphasic formulation of norgestimate with 35 micrograms of ethinyl estradiol (Ortho Tri-Cyclen) was one of the first oral contraceptives to receive FDA approval specifically for treating moderate acne in women who also want contraception. The evidence behind that approval came from randomized, placebo-controlled trials that showed significant skin improvement.

In one trial, women taking the pill saw their inflammatory acne lesion count drop by about 62% over six cycles, compared to roughly 39% in the placebo group.¹⁰ A second placebo-controlled trial reported a 51% reduction in inflammatory lesions for the active group versus about 35% for placebo, with investigators rating over 83% of the treatment group as improved by the study’s end.¹¹ A smaller pilot study confirmed these trends and additionally documented a significant reduction in skin surface oils.¹²

The mechanism is straightforward: ethinyl estradiol stimulates the liver to produce more sex hormone-binding globulin (SHBG), which binds up free testosterone in the blood. Less free testosterone means less sebum production and fewer clogged pores. Norgestimate’s low androgenicity matters here because a more androgenic progestin would partially counteract this effect. The combination of norgestimate with 35 micrograms of ethinyl estradiol raised SHBG levels significantly more than a levonorgestrel-based pill and lowered free testosterone by about 30% compared to levonorgestrel-containing formulations.¹³ A separate head-to-head trial against a norethindrone acetate pill confirmed that norgestimate-ethinyl estradiol had a significantly greater effect on both SHBG and free testosterone.¹⁴ Acne improvement typically takes two to three cycles to become noticeable, so patience matters.

Blood Clot Risk Compared to Other Progestins

All combined oral contraceptives raise the risk of venous thromboembolism (blood clots in the legs or lungs) compared to not using hormonal birth control. The degree of that increase varies by progestin type, and this is where norgestimate has a meaningful advantage. A case-control study comparing norgestimate and desogestrel pills to levonorgestrel pills found that norgestimate users had essentially the same clot risk as levonorgestrel users, with an adjusted odds ratio of 1.1. Desogestrel users, by contrast, had nearly double the risk of levonorgestrel users. The estimated clot rate was about 31 per 100,000 woman-years for norgestimate users and 27 per 100,000 for levonorgestrel users, a difference that was not statistically significant.¹⁵

This finding is consistent with a broader review characterizing norgestimate as the progestin associated with the lowest venous clot risk among combined hormonal contraceptives.¹⁶ For perspective, the absolute risk remains small for healthy, non-smoking women under 35. But if you have a family history of clotting disorders or other risk factors, the progestin choice may matter to your clinician.

On the arterial side, meaning heart attacks and strokes, a large study looking at contemporary hormonal contraceptives found that norgestimate pills with 30-40 micrograms of ethinyl estradiol carried roughly a twofold increase in ischemic stroke and heart attack risk compared to non-users, with adjusted rate ratios of about 1.9 for both outcomes. These numbers were essentially identical to what was seen with levonorgestrel-containing pills and gestodene pills at the same estrogen dose.¹⁷ In other words, for arterial events, the progestin type matters less than the presence of ethinyl estradiol itself.

Lipid and Metabolic Effects

Combined pills affect cholesterol levels, and the direction of that effect depends heavily on the progestin. A meta-analysis of oral contraceptive effects on metabolic markers found that norgestimate-containing pills increased LDL cholesterol by an average of about 12 mg/dL.¹⁸ That might sound concerning, but a longer-term study tracked women on triphasic norgestimate-ethinyl estradiol for two years and found that HDL cholesterol (the “good” kind) rose by about 13%, while the ratio of LDL to HDL actually improved over time. Fasting blood sugar, insulin, and glycated hemoglobin showed no meaningful changes.¹⁹ The take-home is that while norgestimate pills can nudge LDL upward, the concurrent rise in HDL generally keeps the overall lipid picture neutral or mildly favorable. For women with pre-existing dyslipidemia, a prescriber may still want to monitor lipid panels.

Mood and Sexual Interest

Mood changes are one of the most common reasons people consider stopping or switching birth control, and the evidence for norgestimate-ethinyl estradiol reflects the messy reality of this topic. A study comparing two triphasic norgestimate formulations (one with 35 micrograms of ethinyl estradiol, one with 25) found wide individual variation. Some women experienced worsening mood, others felt better, and some noticed no change at all. The lower-estrogen version was more likely to improve premenstrual mood.²⁰ Sexual interest scores did not change significantly from baseline with either formulation in that study.

Separately, a study focused specifically on women who already had severe premenstrual symptoms found that norgestimate-ethinyl estradiol (250 micrograms/35 micrograms) significantly improved both negative mood and physical symptoms like bloating. Women who started with only mild or no symptoms, however, saw no significant changes in either direction.²¹ The pattern that emerges is that if you already have strong cyclical mood swings, the pill may help by smoothing hormonal fluctuations. If your baseline mood is fine, the pill is unlikely to improve it and carries a small chance of making things worse for some individuals. Clinical trial data cannot predict what will happen to any single person, which is why a trial period of two to three months is standard advice before deciding the pill “doesn’t work” for you.

Menstrual Symptoms and Period Pain

Beyond mood, norgestimate-ethinyl estradiol was associated with sharp reductions in dysmenorrhea (period pain) and premenstrual syndrome in a clinical evaluation study.²² This is not unique to norgestimate-based pills; most combined contraceptives lighten periods and reduce cramping because they thin the uterine lining and suppress prostaglandin production. But it is worth noting for anyone considering this particular formulation for reasons beyond pregnancy prevention.

Drug Interactions Worth Knowing About

One of the more clinically significant drug interactions involves efavirenz, an HIV medication. When efavirenz was given alongside norgestimate-ethinyl estradiol, the levels of the active progestin metabolite in the blood dropped dramatically, with peak concentrations falling by about 46% and overall exposure plummeting by 64%. Trough levels, the lowest point between doses, dropped by 82%.²³ Ethinyl estradiol levels were largely unaffected, meaning the progestin component bore the brunt of the interaction. Reductions this large could compromise contraceptive effectiveness, so backup or alternative contraception is typically recommended for people on efavirenz.

Efavirenz is a potent inducer of certain liver enzymes that metabolize steroid hormones, and similar interactions can occur with other enzyme-inducing drugs, including some anti-seizure medications (like carbamazepine and phenytoin) and the antibiotic rifampin. If you take any medication chronically and are starting norgestimate-ethinyl estradiol, a pharmacist check for interactions is a straightforward precaution.

Body Weight and Effectiveness

A recurring concern with oral contraceptives is whether they work less well in heavier women. An analysis of two low-dose norgestimate-ethinyl estradiol formulations found a small, non-significant trend toward higher pregnancy risk in women with a BMI of 25 or above. For those on norgestimate-ethinyl estradiol specifically, the relative risk was about 1.4 compared to women with a lower BMI, but the confidence interval was wide and crossed 1.0, meaning the finding could easily be due to chance.²⁴ Current guidelines do not restrict oral contraceptive use based on weight alone, though some clinicians prefer higher-dose formulations for patients with significantly elevated BMI.

Fertility After Stopping

A systematic review and meta-analysis of contraceptive discontinuation studies found that about 83% of women became pregnant within 12 months of stopping any contraceptive method. Former oral contraceptive users had a slightly higher pooled rate of around 87%. The type of progestin and the duration of pill use did not significantly influence how quickly fertility returned.²⁵ Some people experience a cycle or two of irregular periods after stopping, but this is generally temporary, and there is no evidence that norgestimate-containing pills delay fertility any more than other formulations.

Breast Cancer and Norgestimate Formulations

The relationship between combined oral contraceptives and breast cancer risk has been studied for decades, and the overall picture is that current or recent use slightly raises the risk, which fades after discontinuation. When researchers looked at specific progestin types, norgestimate-containing pills did not appear to carry a statistically significant increase in breast cancer risk. One study estimated an odds ratio of 1.2 for norgestimate pills, compared to 1.5 for levonorgestrel pills, but neither result was statistically distinguishable from other progestin types.²⁶ A separate analysis of breast pathology among users of specific norgestimate formulations found associations with benign breast conditions and lower-risk tumor subtypes rather than aggressive cancers, though these findings are preliminary and should not be over-interpreted.²⁷

Effects on Bone Turnover

Combined oral contraceptives have a complicated relationship with bone health. In adolescents and young women who are still building peak bone mass, some evidence suggests that combined pills may slightly slow bone accrual, with lower estrogen doses potentially having less protective effects than standard doses.²⁸ In a different clinical scenario, a placebo-controlled trial looked at norgestimate-ethinyl estradiol in young women who had stopped menstruating due to hypothalamic amenorrhea and already had low bone density. The pill significantly reduced markers of bone resorption and bone formation, essentially slowing bone turnover.²⁹ Whether reduced turnover translates into actual gains in bone density in that population remains uncertain and likely depends on whether the underlying cause of the amenorrhea is also addressed. For women with normal menstrual function, standard-dose norgestimate-ethinyl estradiol is not considered a bone health concern.

Where Norgestimate Sits Among the “Third-Generation” Progestins

Norgestimate is often grouped with desogestrel and gestodene as a “third-generation” progestin, a label that refers to when these compounds were developed rather than any formal regulatory designation. All three were designed to reduce androgenic side effects compared to older progestins like levonorgestrel and norethindrone.³⁰ But the three are not interchangeable. As the clot data above illustrate, desogestrel carries a higher venous thromboembolism risk than norgestimate. And while norgestimate’s prodrug status means it eventually generates levonorgestrel, its overall hormonal profile in the body looks quite different from taking levonorgestrel directly. The practical upshot is that “third-generation progestin” is a historical category, not a guide to clinical behavior. Prescribing decisions should be based on each drug’s individual data rather than its generational label.